The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better

This review distills modern lipid management into four words: lower for longer is better. From the Johns Hopkins lipid group, it argues that what damages arteries is cumulative LDL exposure — “cholesterol-years” — so both how low you go and how early you start matter.

Several practical anchors stand out. Every 39 mg/dL (1 mmol/L) drop in LDL cuts cardiovascular events by 20–25%. There is no demonstrated floor below which lowering stops helping or starts harming — long-term follow-up of very low LDL has been reassuring. Coronary calcium helps personalize primary prevention (a score over 100 favors a statin; a zero may allow deferral, except in diabetes, smoking, or familial hypercholesterolemia). And for very-high-risk secondary prevention, the target is under 55 mg/dL, reached by stacking statin, ezetimibe, and a PCSK9 inhibitor as needed.

The practical takeaway is an escalation discipline: start early, lower hard, and don’t settle for “good enough” — intensify until target. The resistance is the older threshold mindset and a lingering hesitation to push LDL very low.

We rate the evidence high: an authoritative synthesis from recognized lipid experts, integrating trials, meta-analyses, and current guidelines, though narrative by design. Its clinical significance is high — lipid management is the core of preventive cardiology, and the “lower for longer” framing, with clear decision tables, is directly actionable.